466 related articles for article (PubMed ID: 10713166)
1. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
Gregory MA; Hann SR
Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
[TBL] [Abstract][Full Text] [Related]
2. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover.
Bahram F; von der Lehr N; Cetinkaya C; Larsson LG
Blood; 2000 Mar; 95(6):2104-10. PubMed ID: 10706881
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
4. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.
Gavioli R; Frisan T; Vertuani S; Bornkamm GW; Masucci MG
Nat Cell Biol; 2001 Mar; 3(3):283-8. PubMed ID: 11231578
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitylation and destruction of endogenous c-mycS by the proteasome: are myc boxes dispensable?
Chen L; Smith L; Accavitti-Loper MA; Omura S; Bingham Smith J
Arch Biochem Biophys; 2000 Feb; 374(2):306-12. PubMed ID: 10666312
[TBL] [Abstract][Full Text] [Related]
6. Degradation of proto-oncoprotein c-Rel by the ubiquitin-proteasome pathway.
Chen E; Hrdlickova R; Nehyba J; Longo DL; Bose HR; Li CC
J Biol Chem; 1998 Dec; 273(52):35201-7. PubMed ID: 9857058
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
[TBL] [Abstract][Full Text] [Related]
8. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability.
Nakagawa K; Yokosawa H
Eur J Biochem; 2000 Mar; 267(6):1680-6. PubMed ID: 10712599
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.
Orlowski RZ; Eswara JR; Lafond-Walker A; Grever MR; Orlowski M; Dang CV
Cancer Res; 1998 Oct; 58(19):4342-8. PubMed ID: 9766662
[TBL] [Abstract][Full Text] [Related]
10. Evidence for involvement of calpain in c-Myc proteolysis in vivo.
Small GW; Chou TY; Dang CV; Orlowski RZ
Arch Biochem Biophys; 2002 Apr; 400(2):151-61. PubMed ID: 12054425
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
12. Implication of the ubiquitin/proteasome system in Myc-regulated transcription.
von der Lehr N; Johansson S; Larsson LG
Cell Cycle; 2003; 2(5):403-7. PubMed ID: 12963825
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes.
Boudjelal M; Wang Z; Voorhees JJ; Fisher GJ
Cancer Res; 2000 Apr; 60(8):2247-52. PubMed ID: 10786691
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
15. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.
Aviel S; Winberg G; Massucci M; Ciechanover A
J Biol Chem; 2000 Aug; 275(31):23491-9. PubMed ID: 10807912
[TBL] [Abstract][Full Text] [Related]
16. myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome.
Flinn EM; Busch CM; Wright AP
Mol Cell Biol; 1998 Oct; 18(10):5961-9. PubMed ID: 9742113
[TBL] [Abstract][Full Text] [Related]
17. CAD, a c-Myc target gene, is not deregulated in Burkitt's lymphoma cell lines.
Mac SM; Farnham PJ
Mol Carcinog; 2000 Feb; 27(2):84-96. PubMed ID: 10657901
[TBL] [Abstract][Full Text] [Related]
18. Emerging molecular networks in Burkitt's lymphoma.
Mangani D; Roberti A; Rizzolio F; Giordano A
J Cell Biochem; 2013 Jan; 114(1):35-8. PubMed ID: 22903691
[TBL] [Abstract][Full Text] [Related]
19. In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome.
Bonvini P; Nguyen P; Trepel J; Neckers LM
Oncogene; 1998 Mar; 16(9):1131-9. PubMed ID: 9528855
[TBL] [Abstract][Full Text] [Related]
20. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
Patrick GN; Zhou P; Kwon YT; Howley PM; Tsai LH
J Biol Chem; 1998 Sep; 273(37):24057-64. PubMed ID: 9727024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
